edivoxetine
Small moleculeexperimental
Edivoxetine is a drug which acts as a selective norepinephrine reuptake inhibitor and was under development by Eli Lilly for attention-deficit disorder (ADD) and as an antidepressant treatment. It was in phase III clinical trials in 2012 for major depressive disorder, but failed to get approval. — Wikipedia
Clinical trial activity
27 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
16
Phase 2
8
Phase 3
9
Phase 4
0
Earliest trial started Dec 1, 2006 (NCT00420004)
Timeline
Indications
Mechanism of action
- Norepinephrine transporterINHIBITOR
SLC6A2 inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
COc1ccc(F)cc1C[C@@](O)(C1CCOCC1)[C@@H]1CNCCO1- Mol. weight
- 339.41 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaEdivoxetine ↗
- ChEMBLCHEMBL2103857 ↗
Also known as
- alpha-((5-fluoro-2-methoxyphenyl)methyl)-alpha-(tetrahydro-2h-pyran-4-yl)-2-morpholinemethanol
- edivoxetine
- edivoxetine
- edivoxetine
- edivoxetine
- ly2216684
- ly2216684
- ly2216684
- ly 2216684
- ly-2216684
- ly-2216684
- ly-2216684
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00965419 | Phase 2/Phase 3 (Phase 3) | Aug 1, 2014 | Eli Lilly |
| NCT01460381 | Phase 1 | Oct 1, 2011 | Eli Lilly |
| NCT01460407 | Phase 1 | Oct 1, 2011 | Eli Lilly |
| NCT01370499 | Phase 3 | Aug 1, 2011 | Eli Lilly |
| NCT01389752 | Phase 1 | Jul 1, 2011 | Eli Lilly |
| NCT01389765 | Phase 1 | Jul 1, 2011 | Eli Lilly |
| NCT01380691 | Phase 1 | Jun 1, 2011 | Eli Lilly |
| NCT01373931 | Phase 1 | Jun 1, 2011 | Eli Lilly |
| NCT01299272 | Phase 3 | May 1, 2011 | Eli Lilly |
| NCT01185340 | Phase 3 | Mar 1, 2011 | Eli Lilly |
| NCT01187407 | Phase 3 | Mar 1, 2011 | Eli Lilly |
| NCT01263106 | Phase 1 | Dec 1, 2010 | Eli Lilly |
| NCT01263093 | Phase 1 | Dec 1, 2010 | Eli Lilly |
| NCT01263119 | Phase 1 | Dec 1, 2010 | Eli Lilly |
| NCT01263197 | Phase 1 | Dec 1, 2010 | Eli Lilly |
| NCT01263223 | Phase 1 | Dec 1, 2010 | Eli Lilly |
| NCT01266590 | Phase 1 | Dec 1, 2010 | Eli Lilly |
| NCT01275144 | Phase 1 | Dec 1, 2010 | Eli Lilly |
| NCT01250873 | Phase 1 | Nov 1, 2010 | Eli Lilly |
| NCT01173601 | Phase 3 | Nov 1, 2010 | Eli Lilly |
Showing 20 of 27 trials
Page 1 / 2
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Eli Lilly | For profit | 27 | 27 | 3 | 2006 |
1 organizations
Page 1 / 1